Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy

被引:0
作者
YKY Lai
WY Shen
M Brankov
CM Lai
IJ Constable
PE Rakoczy
机构
[1] Lions Eye Institute,Department of Molecular Ophthalmology
[2] Centre for Ophthalmology and Visual Science,undefined
[3] University of Western Australia,undefined
来源
Gene Therapy | 2002年 / 9卷
关键词
secretion gene therapy; vascular endothelial growth factor; sFlt-1; adeno-associated virus; ocular neovascularisation; inhibition;
D O I
暂无
中图分类号
学科分类号
摘要
Neovascularisation (NV) within the eye often results in visual loss. Vascular endothelial growth factor (VEGF) has been implicated in the development of ocular NV. Previous studies have shown that VEGF antagonists successfully suppressed retinal and choroidal NV in animal models. However, the systemic approach and transient nature of the delivery systems used in these studies hinder therapeutic application. To achieve stable and localised ocular anti-angiogenic therapy, we explored the use of recombinant adeno-associated virus (rAAV)-mediated secretion gene therapy (SGT). In this study, we generated a rAAV vector encoding soluble VEGF receptor 1, sFlt-1 (AAV-CMV.sflt) and determined its ability to inhibit cautery-induced corneal NV and laser-induced choroidal NV. Delivery of AAV-CMV.sflt into the anterior chamber resulted in transgene expression in the iris pigment epithelium and corneal endothelium, which reduced the development of corneal NV in the stroma of cauterised rats by 36% compared with cauterised control groups (P = 0.009). Subretinal delivery of AAV-CMV.sflt near the equator of the eye also suppressed choroidal NV at the laser lesions around the optic nerve by 19% (P = 0.002), indicating that there was diffusion of the secreted anti-angiogenic protein across the retina. Both results suggest that the long-term suppression of ocular NV is possible through the use of stable rAAV-mediated SGT.
引用
收藏
页码:804 / 813
页数:9
相关论文
共 71 条
[31]  
Duan D(2001) transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor Br J Ophthalmol 85 1086-1091
[32]  
Engelhardt JF(2000)Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularisation and normal retina and choroid up to 7 weeks after treatment Gene Therapy 7 1027-1033
[33]  
Maguire A(1996)Visual results after surgical removal of subfoveal choroidal neovascular membranes Biochem Biophys Res Commun 226 324-328
[34]  
Flannery J(1996)Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy Proc Natl Acad Sci USA 93 4851-4856
[35]  
Pierce E(1995)Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes Proc Natl Acad Sci USA 92 10457-10461
[36]  
Yi XV(2000)Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerisation with KDR Am J Pathol 156 697-707
[37]  
Shen WY(2002)Oligodeoxynucleotides inhibit retinal neovascularisation in a murine model of proliferative retinopathy Lab Invest 82 167-182
[38]  
Marmor MF(2000)Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Gene Therapy 7 978-985
[39]  
Marmor MF(2000)Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularisation Invest Ophthalmol Vis Sci 41 2821-2826
[40]  
Negi A(2001)Pre-clinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey J Cell Physiol 188 253-263